Compare MasterCard Inc (MA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Merck & Co., Inc. — how do they compare? MasterCard Inc trades at $547 (market cap $483.71B), while Merck & Co., Inc. trades at $126.29 (market cap $307.25B). The key difference: MasterCard Inc is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MA | MRK | |
|---|---|---|
Market Cap | $483.71B | $307.25B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $129.52 |
52-Week Low | $471.55 | $77.60 |
Enterprise Value | $494.45B | $350.66B |
Dividend Yield | 0.64% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $537.76, down 1.07% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates exceptional profitability with 45.88% net margins and consistent earnings beats, including Q1 2026 EPS of $4.60 beating expectations of $4.41. Revenue growth remains robust, climbing from $22.2B in 2022 to $32.8B in 2025, while institutional buying activity continues to support the stock.
Mastercard presents a compelling growth story with strong fundamentals and analyst support, though elevated valuation metrics and competitive payment innovations warrant monitoring. The consensus price target of $634.27 suggests 18% upside potential, supported by 79% analyst buy ratings. Key risks include payment industry disruption from stablecoins and AI-driven payment systems.
MRK trades at $126.33, down 0.92% on the day, with a neutral technical signal. The company reported strong 2025 results with revenue of $65.01B and net income of $18.25B, beating EPS estimates in recent quarters. Analyst consensus is bullish with a $137.30 price target, and recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is positive, supported by robust profitability and strategic acquisitions, though risks include rising debt levels and competitive pressures. The stock offers a dividend yield with a recent $0.85 payout, and institutional buying activity indicates confidence in long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
